



AGENDA

Miltenyi Cell and Gene Therapy Summit
October 8-9, 2024

Bergisch Gladbach, Germany

Miltenyi Cell and Gene Therapy Summit 2024:

where academic innovation
meets industry expertise

► miltenyibiotec.com



Miltenyi Biotec

DAY 1 October 8, 2024

AGENDA

11:00 a.m. Registration and lunch

12:45 a.m. Day 1 welcome address

01:00 p.m. **Session I**
Translating CGT from academia
to industry*

**Obe-cel cell therapy manufacturing
process development**

Kostadinka Lilova, PhD, Executive Director,
Cell Process Development, Product Delivery,
Autolus Therapeutics, UK

**BNT211-01: Interim results from a repeat
dose escalation study of CLDN6 CAR-T cells
manufactured with an automated process
± a CLDN6-encoding CAR T cell-amplifying
RNA vaccine (CARVac)**

Heidi Gillenwater, MD, Vice President Clinical
Development, Portfolio CGT, BioNTech,
Germany

**Implementation of a Phase I clinical trial to
test CAR T cells against ALK in refractory/
relapsed neuroblastoma**

Roberto Chiarle, MD, Professor of Pathology,
Turin University, Italy / Boston Children's
Hospital, Dana Farber Cancer Institute, USA

**Developing off-the-shelf CAR NK cells
targeting CD70: Updates from preclinical
studies to early clinical trials in an
academic setting**

Sunil Acharya, PhD, Principal Research
Scientist, MD Anderson Cancer Center, USA

03:00 p.m. Break

*denotes a session that will be recorded

**03:30 p.m. Panel discussion
Translating CGT from academia
to industry***

Moderator:

Moderator: Boris Engels, PhD, Senior
Scientific Director, Miltenyi Biotec

Panelists:

Kostadinka Lilova, PhD, Executive Director,
Cell Process Development, Product Delivery,
Autolus Therapeutics, UK

Heidi Gillenwater, MD, Vice President Clinical
Development, Portfolio CGT, BioNTech,
Germany

Roberto Chiarle, MD, Professor of Pathology,
Turin University, Italy / Boston Children's
Hospital, Dana Farber Cancer Institute, USA

Sunil Acharya, PhD, Principal Research
Scientist, MD Anderson Cancer Center, USA

Silvio Weber, PhD, Scientific Director
Industrial Workflow Development Cellular
Therapy, Miltenyi Biotec, Germany

Tony (Bizou) Liu, Chairman and CEO,
AbelZeta, China

04:30 p.m. Miltenyi Tasting Tour:
Visit the Miltenyi Innovation and Technology
Center (MITC) to see Miltenyi Biotec's CGT
manufacturing and analytics solutions.

Miltenyi R&D poster discussion: Discuss
a variety of topics and connect with
Miltenyi R&D experts accompanied with a
refreshment.

07:30 p.m. Networking dinner

DAY 2 October 9, 2024

AGENDA

08:45 a.m. **Day 2 welcome address – Track A (House 4, Skydome) and Track B (House 7, MITC)**

09:00 a.m. **Session II and Panel discussion - Track A/Track B**

Track A – House 4, Skydome – Academic CGT development from hematology to solid tumors*

Challenges of cellular immunotherapy for glioblastoma and other solid tumors
David Reardon, MD, Clinical Director, Center for Neuro-oncology, Dana Farber Cancer Institute, Boston, MD, USA

Development of investigator-initiated CAR T trial for ALL in Korea
Hyoung Jin Kang, MD, Professor and specialist of Pediatric Hematology and Oncology, Seoul National University Hospital, South Korea

Advancing CAR T cell therapy in AML
Marion Subklewe, MD, Head of Cellular Immunotherapy, Department of Hematology & Oncology, LMU - University Hospital of Munich, Germany

Track B – House 7, MITC – Challenges and opportunities in CGT biotech

Arming CAR T cells for potent bystander anti-tumor immune responses

Magnus Essand, PhD, Professor of Gene Therapy, Uppsala University / Co-founder and CSO, Elicera, Uppsala, Sweden

Developing targeted TCR-T therapies: Insights into Immatix's advanced clinical autologous programs and next generation allogeneic platform development

Norbert Hilf, Vice President, Translational Development, Immatix, Germany and Nina Möker, Vice President, Development Lead ACTallo® Platform, Immatix, Germany

Key considerations for shortening your CAR T manufacturing process

Nadine Mockel-Tenbrinck, Manager for Process Engineering, CMC Research, and NCD, Miltenyi Biotec, Germany

11:00 a.m. Lunch

12:00 a.m. Session III Academic developers toward marketing authorization*

Enabling effective simultaneous immunosuppression and support of immune regulation by CRISPR/Cas9 edited tacrolimus-resistant Tregs

Leila Amini, PhD, Head of Regulatory Affairs BeCAT, Charité, Germany

Academic model for CAR T development in multiple myeloma: Clinical results with ARI0002h and future plans

Carlos Fernández de Larrea, MD, Hematologist and Principal Investigator, Hospital Clínic Barcelona, Spain

Roadmap for approval and access of ATMPs in the EU: Focus on policy challenges

Erwan Gicquel, PharmD, Government Affairs Lead, Europe, Miltenyi Biomedicine

*denotes a session that will be recorded

01:30 p.m.

Panel discussion

The CGT ecosystem: role of academia and industry in increasing accessibility to cell therapies*

Moderator:

Cristina Conforti Andreoni, PhD, Portfolio Strategy Manager, Immunotherapy, Miltenyi Biotec

Panelists:

Leila Amini, PhD, Head of Regulatory Affairs BeCAT, Charité, Germany

Carlos Fernández de Larrea, MD, Hematologist and Principal Investigator, Hospital Clínic Barcelona, Spain

Jürgen Kubal, MD, Chair of the Department of Hematology at the UMC Utrecht Cancer Centre, The Netherlands

Erwan Gicquel, PharmD, Government Affairs Lead, Europe, Miltenyi Biomedicine

Claudia Rossig, MD, University Children's Hospital, Pediatric Hematology and Oncology, Münster, Germany

So Ra Park, MD, Chair & Founder, Regenerative Medicine Acceleration Foundation (RMAF), South Korea

Michael Kahnert, Manager Government Affairs, Miltenyi Biotec, Germany

02:30 p.m.

Closing remarks, light lunch/lunch box, and departure



Miltenyi Biotec

Miltenyi Biotec B.V. & Co. KG

Friedrich-Ebert-Straße 68 | 51429 Bergisch Gladbach | Germany

Phone +49 2204 8306-0 | Fax +49 2204 85197

macsde@miltenyi.com | www.miltenyibiotec.com

Miltenyi Biotec provides products and services worldwide.

Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

The statements and other contributions presented at the meeting and the views expressed therein are those of the attending experts and do not necessarily represent the policy or opinion of Miltenyi Biotec or any institution the respective expert may be associated with. Neither Miltenyi Biotec nor any of its directors or employees give any representation or warranty as to the reliability, accuracy, or completeness of the content thereof. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This notice must accompany any further distribution of this document.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. Copyright © 2024 Miltenyi Biotec and/or its affiliates. All rights reserved.